Actinogen Medical Ltd: ACW June 2024 quarterly activity report & Appendix 4C
Actinogen Medical Ltd: ACW XanaCIDD depression trial results expected early August
Actinogen Medical Ltd: Positive Xanamem biomarker trial published in Jnl Alz Dis
Actinogen Medical Ltd: Appendix 3Ys x 5
Actinogen Medical Ltd: ACW Clinical Trials Science Forum 23 May registration detail
Actinogen Medical Ltd: Trading Halt
Actinogen Medical Ltd: ACW March 2024 quarterly activity report & Appendix 4C
Actinogen Medical Ltd: ACW completes cognition & depression phase 2 trial enrolment
Actinogen Medical Ltd: First patient treated in ACW XanaMIA ph 2b Alzheimers trial
Actinogen Medical Ltd: Appendix 3Y-Mr Malcolm McComas
Actinogen Medical Ltd: ACW XanaCIDD depression trial enters final enrolment phase
Actinogen Medical Ltd: Actinogen CMO presents at ADPD 2024 conference
Actinogen Medical Ltd: Response to ASX Aware Query
Actinogen Medical Ltd: Actinogen awarded UK Innovation Passport for Xanamem
Actinogen Medical Ltd: ACW December 2023 quarterly activity report & Appendix 4C
Actinogen Medical Ltd: Positive Xanamem brain PET study peer-reviewed publication
Actinogen Medical Ltd: First site activated in ACW XanaMIA Phase 2b AD trial
Actinogen Medical Ltd: Appendix 3Ys x 5
Actinogen Medical Ltd: Appendix 3Y-Dr George Morstyn
Actinogen Medical Ltd: Appendix 3Y-Dr Geoff Brooke
No Data